利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

53 条记录 (耗时 0.051 秒)

    Saccharin derivative proteolytic enzyme inhibitors
    4.
    发明授权
    Saccharin derivative proteolytic enzyme inhibitors 失效
    糖精衍生蛋白水解酶抑制剂

    公开(公告)号：US5578623A

    公开(公告)日：1996-11-26

    申请号：US445240

    申请日：1995-05-19

    申请人： Richard P. Dunlap ,  Albert J. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    发明人： Richard P. Dunlap ,  Albert J. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    IPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541 ,  A61K31/425 ,  C07D275/04

    CPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541

    摘要： Compounds having the structural formula ##STR1## wherein L is O;L-R.sup.1 is a leaving group, H-L-R.sup.1 is the conjugate acid thereof and H-L-R.sup.1 has a pK.sub.a value less than or equal to to 8;R.sup.2 is primary or secondary alkyl of two to four carbon atoms, primary alkylamino of one to three carbon atoms, primary alkylmethylamino of two to four carbon atoms, diethylamino or primary alkoxy of one to three carbon atoms; andR.sup.3 is from one to three of a variety of substituents at any or all of the 5-, 6- and 7-positions;or a pharmaceutically acceptable acid addition salt thereof if the compound has a basic functional group or a pharmaceutically acceptable acid addition salt thereof if the compound has an acidic functional group,which inhibit the enzymatic activity of proteolytic enzymes, and processes for preparation thereof, method of use thereof in treatment of degenerative diseases and pharmaceutical compositions thereof are disclosed.

    摘要翻译： 具有式I的结构式的化合物，其中L是O; L-R1是离去基团，H-L-R1是其共轭酸，H-L-R1具有小于或等于8的pKa值; R2是2至4个碳原子的伯或仲烷基，1至3个碳原子的伯烷基氨基，2至4个碳原子的伯烷基甲基氨基，1至3个碳原子的二乙氨基或伯烷氧基; 在任何或全部5-，6-和7-位上，R 3是1-3个各种取代基; 如果该化合物具有抑制蛋白水解酶的酶活性的酸性官能团，则该化合物具有碱性官能团或其药学上可接受的酸加成盐，或其药学上可接受的酸加成盐，及其制备方法， 公开了其在治疗退行性疾病中的用途及其药物组合物。

    Saccharin derivative proteolytic enzyme inhibitors
    6.
    发明授权
    Saccharin derivative proteolytic enzyme inhibitors 失效
    糖精衍生蛋白水解酶抑制剂

    公开(公告)号：US5464852A

    公开(公告)日：1995-11-07

    申请号：US289113

    申请日：1994-08-11

    申请人： Richard P. Dunlap ,  Albert J. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    发明人： Richard P. Dunlap ,  Albert J. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    IPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541 ,  A61K31/425 ,  A61K31/41 ,  C07D249/04

    CPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541

    摘要： Compounds having the structural formula ##STR1## wherein L is N, O or SO.sub.n wherein n is 0, 1 or 2;L--R.sup.1 is a leaving group, H--L--R.sup.1 is the conjugate acid thereof and,when L is N, H--L--R.sup.1 has a pK.sub.a value less than or equal to 6, when L is O, H--L--R.sup.1 has a pK.sub.a value less than or equal to to 8, and when L is SO.sub.n, H--L--R.sup.1 has a pK.sub.a value less than or equal to 5;R.sup.2 is primary or secondary alkyl of two to four carbon atoms, primary alkylamino of one to three carbon atoms, primary alkylmethylamino of two to four carbon atoms, diethylamino or primary alkoxy of one to three carbon atoms; andR.sup.3 is from one to three of a variety of substituents at any or all of the 5-, 6- and 7-positions;or a pharmaceutically acceptable acid addition salt thereof if the compound has a basic functional group or a pharmaceutically acceptable base addition salt thereof if the compound has an acidic functional group,which inhibit the enzymatic activity of proteolytic enzymes, and processes for preparation thereof, method of use thereof in treatment of degenerative diseases and pharmaceutical compositions thereof are disclosed.

    摘要翻译： 具有式I的结构式的化合物，其中L是N，O或SO，其中n是0,1或2; L-R1是离去基团，HL-R1是其共轭酸，当L为N时，HL-R1的pKa值小于或等于6，当L为O时，HL-R1的pKa值较小 在L为SOn时，HL-R1的pKa值小于等于5; R2是2至4个碳原子的伯或仲烷基，1至3个碳原子的伯烷基氨基，2至4个碳原子的伯烷基甲基氨基，1至3个碳原子的二乙氨基或伯烷氧基; 在任何或全部5-，6-和7-位上，R 3是1-3个各种取代基; 如果该化合物具有抑制蛋白水解酶的酶活性的酸性官能团，则该化合物具有碱性官能团或其药学上可接受的碱加成盐，或其药学上可接受的酸加成盐，及其制备方法， 公开了其在治疗退行性疾病中的用途及其药物组合物。

    Saccharin derivative proteolytic enzyme inhibitors
    7.
    发明授权
    Saccharin derivative proteolytic enzyme inhibitors 失效
    糖精衍生蛋白水解酶抑制剂

    公开(公告)号：US5380737A

    公开(公告)日：1995-01-10

    申请号：US113508

    申请日：1993-08-27

    申请人： Richard P. Dunlap ,  Albert A. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    发明人： Richard P. Dunlap ,  Albert A. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    IPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541 ,  A61K31/425

    CPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541

    摘要： Compounds having the structural formula ##STR1## wherein L is N, O or SO.sub.n wherein n is 0, 1 or 2;L-R.sup.1 is a leaving group, H-L-R.sup.1 is the conjugate acid thereof and, when L is N, H-L-R.sup.1 has a pK.sub.a value less than or equal to 6, when L is O, H-L-R.sup.1 has a pK.sub.a value less than or equal to to 8, and when L is SO.sub.n, H-L-R.sup.1 has a pK.sub.a value less than or equal to 5;R.sup.2 is primary or secondary alkyl of two to four carbon atoms, primary alkylamino of one to three carbon atoms, primary alkylmethylamino of two to four carbon atoms, diethylamino or primary alkoxy of one to three carbon atoms; andR.sup.3 is from one to three of a variety of substituents at any or all of the 5-, 6- and 7-positions;or a pharmaceutically acceptable acid addition salt thereof if the compound has a basic functional group or a pharmaceutically acceptable base addition salt thereof if the compound has an acidic functional group,which inhibit the enzymatic activity of proteolytic enzymes, and processes for preparation thereof, method of use thereof in treatment of degenerative diseases and pharmaceutical compositions thereof are disclosed.

    摘要翻译： 具有式I的结构式的化合物，其中L是N，O或SO，其中n是0,1或2; L-R1是离去基团，HL-R1是其共轭酸，当L为N时，HL-R1的pKa值小于或等于6，当L为O时，HL-R1的pKa值较小 在L为SOn时，HL-R1的pKa值小于等于5; R2是2至4个碳原子的伯或仲烷基，1至3个碳原子的伯烷基氨基，2至4个碳原子的伯烷基甲基氨基，1至3个碳原子的二乙氨基或伯烷氧基; 在任何或全部5-，6-和7-位上，R 3是1-3个各种取代基; 如果该化合物具有碱性官能团或其药学上可接受的碱加成盐，则该化合物具有抑制蛋白水解酶的酶活性的酸性官能团及其制备方法，或其药学上可接受的酸加成盐， 公开了其在治疗退行性疾病中的用途及其药物组合物。